Last reviewed · How we verify
Atezolizumab & Bevacizumab
Atezolizumab blocks PD-L1 to restore anti-tumor immunity, while bevacizumab inhibits VEGF to reduce tumor angiogenesis, together enhancing immune-mediated tumor control.
Atezolizumab blocks PD-L1 to restore anti-tumor immunity, while bevacizumab inhibits VEGF to reduce tumor angiogenesis, together enhancing immune-mediated tumor control. Used for Hepatocellular carcinoma, Advanced or metastatic non-small cell lung cancer, Renal cell carcinoma.
At a glance
| Generic name | Atezolizumab & Bevacizumab |
|---|---|
| Also known as | AtezoBev, AVASTIN, TECENTRIQ, MPDL3280A; Avastin, Bevacizumab |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Drug class | PD-L1 inhibitor + VEGF inhibitor combination |
| Target | PD-L1 and VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Atezolizumab is a PD-L1 inhibitor that releases the brakes on T-cell-mediated anti-tumor immunity by blocking the PD-L1/PD-1 checkpoint. Bevacizumab is a VEGF inhibitor that starves tumors of blood supply and may normalize the tumor vasculature to improve immune cell infiltration. The combination leverages both immune checkpoint relief and anti-angiogenic mechanisms.
Approved indications
- Hepatocellular carcinoma
- Advanced or metastatic non-small cell lung cancer
- Renal cell carcinoma
Common side effects
- Fatigue
- Hypertension
- Proteinuria
- Diarrhea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Bleeding
Key clinical trials
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (PHASE1, PHASE2)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: